BusinessModerna Raises 2026 Revenue Growth Outlook After 29% Year-Over-Year GainBy Helena WardNov 8, 2026, 7:38 PM UTC
InvestingModerna Gains 13.1% Before Results as WHO Panel Recommends Ebola Trial CandidateBy Celia RowanNov 5, 2026, 4:03 AM UTC
InvestingYieldMax Cuts MRNY Weekly Distribution 39.1% to $0.5394By Celia RowanOct 28, 2026, 11:27 PM UTC
HealthINTerpath-001 Results Show 42% Lower Risk of Melanoma Recurrence or DeathBy Naomi CalderOct 24, 2026, 7:06 PM UTC
InvestingHyperliquid Prices Moderna Futures at $190.53 During U.S. Market ClosureBy Celia RowanOct 23, 2026, 9:29 PM UTC
InvestingModerna Shares Fall 17.57% After Melanoma Trial Results Surface EarlyBy Celia RowanOct 23, 2026, 8:19 PM UTC
InvestingModerna Shares Fall 17.57%, Leaving Year-to-Date Gain at 587%By Celia RowanOct 22, 2026, 10:45 PM UTC
